Your session is about to expire
Dexcom G6 vs G7
Introduction
In managing diabetes, continuous glucose monitoring (CGM) systems have proven to be extremely beneficial. Dexcom G6 and G7 are two such devices that can aid in maintaining stable blood sugar levels by providing real-time glucose readings. They each function using different technologies but both aim to provide accurate and timely information for patients with diabetes. Dexcom G6 is a well-established CGM system that allows users to monitor their glucose levels without the need for frequent fingerstick calibrations, it also has an alert feature for high or low sugar levels. The upcoming Dexcom G7, on the other hand, co-developed with Verily (an Alphabet company), promises advanced features including a much smaller wearable profile and extended sensor life while still maintaining the no-fingerstick calibration advantage of its predecessor.
Dexcom G6 vs G7 Side By Side
| Attribute | Dexcom g6 | Dexcom g7 |
|---|---|---|
| Brand Name | Dexcom G6 | Dexcom G7 |
| Contraindications | Cannot be used with certain medical devices like pacemakers or defibrillators | Cannot be used with certain medical devices like pacemakers or defibrillators |
| Cost | Approximately $237 for the transmitter, $349 for a pack of three sensors | Expected to be similar or slightly higher than Dexcom G6 |
| Generic Name | Continuous Glucose Monitoring System | Continuous Glucose Monitoring System |
| Most Serious Side Effect | Allergic reactions on the skin, inaccurate readings leading to mismanagement of insulin dosages | Skin irritation or allergic reaction at the site of sensor insertion, infections due to improper hygiene during sensor application |
| Severe Drug Interactions | Not applicable as it is not a medication | Not applicable as it is not a medication |
| Typical Dose | Sensor replaced every 10 days | Sensor expected to last 14-15 days |
What is Dexcom G6?
Dexcom G6, a continuous glucose monitoring system (CGM), was a significant advancement in diabetes management when it was first introduced. It provides real-time glucose readings every five minutes for people with type 1 or type 2 diabetes, allowing them to track their blood sugar levels without the need for fingerstick calibrations. The device is FDA-approved and has proven to be highly accurate.
Now Dexcom is planning to release an even more refined version of this technology, known as the Dexcom G7. Though details are still emerging about its features, initial reports suggest that it will be smaller and thinner than the G6 model for better wearability. In addition to providing continuous glucose readings, it's expected that the new model will also have a longer sensor life and other improved capabilities.
Just like Prozac had fewer side effects due to its selective influence on serotonin only, similarly Dexcom G7 aims at reducing any discomfort or inconvenience caused by the earlier models by being less intrusive while maintaining high performance in terms of accuracy and reliability.
What conditions is Dexcom G6 approved to treat?
Dexcom G6 and G7 are Continuous Glucose Monitoring (CGM) systems designed to help manage diabetes:
-
Dexcom G6 is approved for people with type 1 or type 2 diabetes aged two years and older. It offers real-time glucose readings every five minutes, allowing users to see their glucose levels and where they're heading.
-
Dexcom G7, the upcoming version of the CGM system which is currently under review by regulatory authorities, promises a slimmer wearable profile than its predecessor while maintaining the same core features. Additionally, it aims to be fully disposable after use, making it more user-friendly.
How does Dexcom G6 help with these illnesses?
Dexcom G7, like its predecessor Dexcom G6, aims to help manage diabetes by providing real-time glucose readings for individuals with either type 1 or type 2 diabetes. It does this through a sensor that is inserted under the skin and continuously measures interstitial glucose levels (the sugar in the fluid between cells), which correlates closely with blood glucose levels.
Whereas Dexcom G6 requires calibration using fingerstick blood glucose measurements, the Dexcom G7 has been designed to work without any need for user calibration. This means it can provide continuous monitoring of your body's glucose levels without needing you to puncture your finger multiple times a day.
Glucose is an essential energy source needed by all the tissues and organs within our bodies. In people with diabetes, their bodies either don't produce enough insulin (a hormone made in the pancreas) or cannot use insulin effectively leading to high blood sugar levels over time. By continuously tracking these levels, both systems help patients better understand how food intake, exercise, medication and lifestyle affect their blood sugar management but with added convenience in case of Dexcom G7.
What is G7?
The Dexcom G7 is the latest iteration of continuous glucose monitoring systems or CGMs, which are designed to provide real-time information about blood sugar levels. This device builds on the strong foundation laid by its predecessor, the Dexcom G6. The key function of these devices is to reduce glucose absorption and increase insulin sensitivity in patients with diabetes. However, while both models share this primary aim, they differ in their design and features.
Dexcom's G7 model distinguishes itself from its predecessor through a more streamlined and compact design that makes it less intrusive for users. It also boasts an extended wear duration compared to the G6, allowing for 10 days of use without changing sensors. Furthermore, unlike the Dexcom G6 system which requires a separate transmitter unit attached to each sensor patch, all necessary components are integrated into one single-use applicator in the newer version.
In addition to these improvements in user experience and convenience factors, another significant point about Dexcom's upgraded model is that it does not require any fingerstick calibration at all - a feature already present but improved upon from its previous iteration (G6). Its lack of requirement for regular manual calibrations means that users can enjoy greater ease-of-use and may gain increased confidence in managing their condition effectively using this tool.
What conditions is G7 approved to treat?
Dexcom G7, the latest model in Dexcom's continuous glucose monitoring systems, is designed to provide several enhancements and advancements over its predecessor. The features of G7 include:
- A smaller profile than the Dexcom G6 allowing for more discretion
- Fully disposable with no separate transmitter
- Extended 10-day wear with zero fingersticks required Please note that as of now, the Dexcom G7 has not yet received FDA clearance and is currently under review.
How does G7 help with these illnesses?
The Dexcom G7, much like its predecessor the G6, is a continuous glucose monitoring (CGM) system that provides real-time glucose readings for individuals with diabetes. It plays an essential role in managing and maintaining optimal blood sugar levels and helps to alleviate some of the daily stresses associated with this chronic condition. The action of the Dexcom G7 builds upon foundations laid by the G6 but offers several advancements. These include improved size reduction, making it even more discreet and comfortable for wearers, as well as an expected longer wear time than its predecessor. Its enhanced features provide increased convenience and precision when compared to traditional fingerstick measurements or even earlier CGM models such as the G6. Thus, it's often prescribed after patients show dissatisfaction or discomfort with previous generation devices.
How effective are both Dexcom G6 and G7?
Both the Dexcom G6 and the upcoming Dexcom G7 are state-of-the-art continuous glucose monitoring (CGM) systems with established reputations for helping manage diabetes efficiently. The FDA approved the G6 in 2018, while the G7 is set to be released soon.
The performance of both CGMs has been evaluated through clinical trials, which have shown that they provide precise and reliable measurements of blood glucose levels. In these studies, no significant differences were found between patients using either device in terms of overall glycemic control.
Dexcom's product development reports indicate that both devices were designed for ease-of-use and comfort. However, a key advantage of the newer model may be its smaller size and integrated design where sensor and transmitter are combined into a single unit - this could make application easier for users.
A review from Dexcom indicated that their products consistently perform well against other CGMs on the market due to their accuracy, predictability capabilities, longevity (up to 10 days), compatibility with various insulin delivery methods as well as integration with smart devices.
Furthermore, it was stated by Dexcom CEO Kevin Sayer that while there will always be improvements made across generations of technology like going from G6 to upcoming G7; providing accurate readings remains at the core since inaccurate data can lead not just inconvenience but potential health risks also.
When comparing current generation Dexom G6 to forthcoming innovative version -G7-, although much information about latter is still under wraps one thing known is miniaturization aspect where new device would reportedly be significantly smaller than previous versions making it more wearable-friendly.
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Dexcom G6 typically prescribed?
The Dexcom G6 Continuous Glucose Monitoring (CGM) System is designed for use in people with diabetes who are two years of age and older. It provides real-time glucose readings every five minutes, allowing users to monitor their blood sugar levels without routine finger pricks. The device features a simple auto-applicator and customizable alerts for low and high blood sugars. The upcoming Dexcom G7 CGM system, on the other hand, promises even more improvements including smaller size, longer wear time up to 14-15 days instead of 10 with the G6 model, as well as an integrated sensor applicator system for easier application. Like its predecessor, the G7 will also provide continuous glucose readings that can be shared with up to ten followers through compatible smart devices.
At what dose is G7 typically prescribed?
The Dexcom G7 Continuous Glucose Monitoring (CGM) system is expected to come with improved features from its predecessor, the G6. Usage of the device begins by installing a small sensor under your skin, which can stay in place for up to 10 days. The data collected by the sensor can then be viewed at any time on your smartphone or other compatible devices. Enhancements in the G7 model include a smaller and slimmer design compared to the G6 for less visibility and greater comfort, as well as an extended wear period of 14-15 days instead of just 10 days like in previous models. It's important to note that these advancements are subject to change based on ongoing clinical trials and regulatory approval process.
What are the most common side effects for Dexcom G6?
Both Dexcom G6 and G7 are continuous glucose monitoring systems designed to help people with diabetes manage their condition. Comparing the two, some potential discomforts or inconveniences associated with these devices could include:
- Skin irritation or rash at the sensor site
- Anxiety from constantly monitoring blood glucose levels
- Nervousness if readings suggest a significant fluctuation in blood sugar
- Discomfort during sensor insertion
- Potential insomnia due to alert notifications for abnormal glucose levels
- Mild pain or swelling at the device site
It's important to note that both devices aim to minimize disruption of daily life while providing accurate and real-time data for better diabetes management. Always consult your healthcare provider when choosing between different medical technologies.
Are there any potential serious side effects for Dexcom G6?
While comparing Dexcom G6 and Dexcom G7, please note that they are not medications but Continuous Glucose Monitoring (CGM) systems used by people with diabetes to measure glucose levels. Potential side effects or issues may include:
- Allergic reactions on the skin where the sensor is attached: redness, swelling, itchiness
- Inaccurate readings leading to mismanagement of insulin dosages
- Discomfort or pain at the insertion site
- Sensor getting dislodged prematurely
Despite these potential problems, CGMs like Dexcom G6 and G7 reduce the need for multiple daily finger pricks and provide real-time glucose trend information. Always consult your doctor if you face any discomfort while using these devices. Follow device-specific instructions carefully for accurate readings.
What are the most common side effects for G7?
The Dexcom G7, while similar in function to the G6, boasts a number of advancements in its technology. Potential issues or discomforts associated with the device might include:
- Skin irritation at the site of sensor application
- Inaccuracy in glucose readings if calibration is not properly done
- Slight discomfort during insertion of the sensor
- Mild anxiety or confusion due to continuous monitoring and result interpretation
- Possible allergic reaction to adhesive used on patches While these potential side effects are generally rare and minor, they should still be taken into account when choosing between devices.
Are there any potential serious side effects for G7?
While the Dexcom G7, like its predecessor the G6, is designed to provide real-time glucose readings with minimal discomfort, some users may experience adverse reactions. Though these are rare, it's important to stay vigilant for signs of:
- Skin irritation or allergic reaction at the site of sensor insertion: redness, swelling, itching or hives.
- Infections due to improper hygiene during sensor application: characterized by fever and localized pain.
- Difficulty breathing or swallowing potentially indicating a serious systemic allergic reaction.
- Unusual changes in mood or behavior possibly linked to incorrect blood sugar reading leading to inappropriate insulin dosing.
- Blurred vision can be a symptom of significant blood sugar irregularities not accurately detected by the device.
It’s crucial that if you're using Dexcom G7 and notice any abnormal symptoms such as these listed above - especially persistent skin issues around your sensor site - please consult with your healthcare provider promptly.
Contraindications for Dexcom G6 and G7?
Both Dexcom G6 and G7 are continuous glucose monitoring (CGM) systems that may revolutionize diabetes management for many people. However, if you notice any issues such as persistent high or low blood sugar readings not corresponding with your symptoms, please seek immediate medical attention.
Neither the Dexcom G6 nor the upcoming G7 can be used if you have been implanted with certain types of medical devices like pacemakers or defibrillators. It's crucial to always inform your healthcare provider about any other medical devices you're using; these could potentially interfere with the communication between CGM transmitters and receivers.
The newer model, the Dexcom G7 is expected to have a longer sensor wear time than its predecessor, lasting up to 15 days compared to the 10-day limit of the Dexcom G6. Always remember that it’s important to replace sensors on schedule as per manufacturer guidelines in order to ensure accurate glucose readings and prevent skin irritation at sensor sites.
How much do Dexcom G6 and G7 cost?
For the brand name versions of these glucose monitoring systems:
- The price for one Dexcom G6 transmitter (which lasts 90 days) is approximately $237, with sensors priced at around $349 for a pack of three which last ten days each. This equates to about $21 per day.
- As the Dexcom G7 system has not yet been released, no exact pricing information is available. However, it's anticipated that costs will be similar or slightly higher than those of the G6.
Thus, if you are in need of continuous glucose monitoring and choosing between the two models based on cost alone (though this should not be your primary consideration), current information suggests that Dexcom G6 will likely be less expensive on a per-day treatment basis until we have accurate pricing information for the new model.
Please note there are no generic versions for these devices as they represent specific branded technologies developed by Dexcom.
Popularity of Dexcom G6 and G7
The Dexcom G6, a continuous glucose monitoring system (CGM), has been widely used by patients with diabetes to monitor their glucose levels in real-time. In 2020, the Dexcom G6 was reported to have had over 900,000 users in the US alone. Its ease of use and ability to provide critical insights about blood sugar trends without fingersticks made it popular among its user base.
On the other hand, Dexcom's latest CGM model - the yet-to-be-released G7 is expected to be even more compact and user-friendly than its predecessor. Although exact numbers of anticipated prescriptions or users are unavailable due to its pending release status as of this writing, anticipation for this newer model is high within the diabetic community because of promises for an extended sensor wear time up from 10 days (as seen with G6) to 14-15 days and fully disposable transmitter which means no separate piece needs removing every ten days like you currently do with your Dexcom G6 transmitter.
Conclusion
Both Dexcom G6 and the upcoming Dexcom G7 are continuous glucose monitoring systems (CGMs) that have revolutionized diabetes management, providing real-time glucose readings for patients with diabetes. Both devices are designed to provide ongoing data about blood sugar levels, helping individuals better manage their condition. The G6 has a well-established reputation for accuracy and ease of use, while the highly anticipated G7 promises advancements in technology and user experience.
The most significant difference between these two models is size; the newer G7 is considerably smaller than its predecessor, making it less noticeable on the body. Also, unlike the Dexcom G6 which requires calibration with fingerstick measurements twice per day during its 10-day wear period, the forthcoming Dexcom G7 will be factory-calibrated and won't require any fingersticks at all.
Both devices offer important features like customizable alerts for high or low blood sugar levels but more specific comparisons will need to wait until after the release and extensive testing of the new model. As always when considering such medical technology changes or upgrades, discussions should take place with your healthcare provider who understands your personal health circumstances best.
Please note: While both systems promise great benefits for managing diabetes effectively, they also come with potential side effects including skin irritation due to adhesive patches or inaccurate readings especially if not calibrated correctly (in case of Dexcom G6). Users should monitor their symptoms closely and report any discomfort or discrepancies immediately to their healthcare provider.
Other Trials to Consider
Popular Categories
Popular Guides
Learn More About These Treatments
Refrences
- Bailey, T., Zisser, H., & Chang, A. (2009, December). New Features and Performance of a Next-Generation SEVEN-Day Continuous Glucose Monitoring System with Short Lag Time. Diabetes Technology & Therapeutics. Mary Ann Liebert Inc.http://doi.org/10.1089/dia.2009.0075
- Garg, S. K., Kipnes, M., Castorino, K., Bailey, T. S., Akturk, H. K., Welsh, J. B., … Beck, S. E. (2022, June 1). Accuracy and Safety of Dexcom G7 Continuous Glucose Monitoring in Adults with Diabetes. Diabetes Technology & Therapeutics. Mary Ann Liebert Inc.http://doi.org/10.1089/dia.2022.0011
- Minnock, P. P., & Howe, C. J. (2011, June). Use of Continuous Glucose Monitoring Systems in Children with Type 1 Diabetes. Critical Care Nursing Clinics of North America. Elsevier BV.http://doi.org/10.1016/j.ccell.2011.04.004
- Facchinetti, A. (2016, December 9). Continuous Glucose Monitoring Sensors: Past, Present and Future Algorithmic Challenges. Sensors. MDPI AG.http://doi.org/10.3390/s16122093
- Welsh, J. B., Psavko, S., Zhang, X., Gao, P., & Balo, A. K. (2022, June 13). Comparisons of Fifth-, Sixth-, and Seventh-Generation Continuous Glucose Monitoring Systems. Journal of Diabetes Science and Technology. SAGE Publications.http://doi.org/10.1177/19322968221099879
- Welsh, J. B., Zhang, X., Puhr, S. A., Johnson, T. K., Walker, T. C., Balo, A. K., & Price, D. (2018, September 10). Performance of a Factory-Calibrated, Real-Time Continuous Glucose Monitoring System in Pediatric Participants With Type 1 Diabetes. Journal of Diabetes Science and Technology. SAGE Publications.http://doi.org/10.1177/1932296818798816
- Garg, S. K., Voelmle, M. K., & Gottlieb, P. (2009, March 1). Feasibility of 10-Day Use of a Continuous Glucose-Monitoring System in Adults With Type 1 Diabetes. Diabetes Care. American Diabetes Association.http://doi.org/10.2337/dc08-1745
- Matuleviciene, V., Joseph, J. I., Andelin, M., Hirsch, I. B., Attvall, S., Pivodic, A., … Lind, M. (2014, November). A Clinical Trial of the Accuracy and Treatment Experience of the Dexcom G4 Sensor (Dexcom G4 System) and Enlite Sensor (Guardian REAL-Time System) Tested Simultaneously in Ambulatory Patients with Type 1 Diabetes. Diabetes Technology & Therapeutics. Mary Ann Liebert Inc.http://doi.org/10.1089/dia.2014.0238
- Kamann, S., Aerts, O., & Heinemann, L. (2018, March 15). Further Evidence of Severe Allergic Contact Dermatitis From Isobornyl Acrylate While Using a Continuous Glucose Monitoring System. Journal of Diabetes Science and Technology. SAGE Publications.http://doi.org/10.1177/1932296818762946
- Solano, L. (2022, September). Seven facts you need to know about continuous glucose monitors. Jaapa. Ovid Technologies (Wolters Kluwer Health).http://doi.org/10.1097/01.jaa.0000854536.09072.5e
- Kim, H., Shin, J., Chang, J., Cho, J., Son, H., & Yoon, K. (2012, December). Continuous glucose monitoring: current clinical use. Diabetes/Metabolism Research and Reviews. Wiley.http://doi.org/10.1002/dmrr.2346